Dexamethasone phosphate
Dexafree is an eye drop in single-dose containers, which contains a substance called dexamethasone. This substance is a corticosteroid that inhibits the symptoms of inflammation. Dexafree is indicated for the treatment of inflammatory conditions of the eye. The eye should not be infected (redness of the eye, discharge, tearing, ...), otherwise, specific anti-infective treatment should be applied at the same time (see section 2).
If the patient has an eye infectionthat may be bacterial (acute purulent infection), fungal, viral (herpes virus, cowpox virus (VACV), chickenpox virus (VZV)), or caused by amoebas, if the patient has corneal damage(perforation, ulceration, or pathological changes associated with incomplete healing (regeneration)), if the patient has been diagnosed with increased intraocular pressurecaused by glucocorticoids (a group of corticosteroids), if the patient is allergic(hypersensitive) to dexamethasone sodium phosphateor any of the other ingredients of Dexafree.
Before starting to use Dexafree, the patient should discuss it with their doctor or pharmacist. DO NOT INJECT, DO NOT SWALLOWDo not touch the tip of the dropper to the eye or eyelids.During the use of Dexafree, strict ophthalmological control is required, especially:
The patient should consult their doctor if they experience swelling and weight gain, particularly on the trunk and face, as these are usually the first symptoms of a condition called Cushing's syndrome. Suppression of adrenal function may occur as a result of discontinuing prolonged or intensive use of Dexafree. The patient should consult their doctor before deciding to stop treatment. This risk is particularly important in children and patients treated with ritonavir or cobicistat. If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
If it is necessary to use other eye drops, the patient should wait 15 minutes before administering the next dose. The patient should tell their doctor if they are taking ritonavir or cobicistat, as these medicines may increase the levels of dexamethasone in the blood. Calcium phosphate precipitation on the surface of the corneal stroma has been observed in cases of concurrent use of local corticosteroids and beta-adrenergic receptor blockers. The patient should tell their doctor or pharmacist about all medicines they are taking, have recently taken, or plan to take.
There is insufficient data on the use of Dexafree in pregnant women. The potential risk to humans is unknown. Therefore, it is not recommended to use Dexafree during pregnancy. It is not known whether the medicine is excreted in breast milk. However, the total dose of dexamethasone is low. Therefore, Dexafree can be used during breastfeeding. If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
As with all eye drops, transient blurred vision or other visual disturbances may affect the ability to drive or operate machinery. The patient should not drive or operate machinery until their vision has returned to normal.
The medicine contains 80 micrograms of phosphates in each drop.
This medicine should always be used exactly as prescribed by the doctor. If the patient is unsure, they should consult their doctor or pharmacist. The recommended dose is 1 drop into the affected eye 4 to 6 times a day. In severe cases, treatment can be started with 1 drop every hour, and after improvement, the dose can be reduced to 1 drop every 4 hours. It is recommended to gradually reduce the dose to avoid relapse.
Administration to the eye: this medicine is intended for use in the eyes.
1. Before using the medicine, wash your hands thoroughly.
2. Looking up and gently pulling down the lower eyelid with your finger, put one drop into the eye that needs treatment.
3. Immediately after instillation, gently pressthe inner corner of the treated eye with your finger for a few minutes (to reduce the risk of systemic reactions and increase the penetration of the active substance into the eye).
After use, discardthe single-dose container. Do not store it for later use.
4 to 6 times a day.
The treatment period usually ranges from a few days to a maximum of 14 days.
In case of administration of too high a dose to the eye and prolonged irritation, the eye should be rinsed with sterile water. The patient should immediately contact their doctor or pharmacist.
The patient should not take a double dose to make up for a missed dose.
The patient should not suddenly stop treatment. They should always consult their doctor if they are considering stopping treatment. If the patient has any further questions about the use of this medicine, they should ask their doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Unknown: frequency cannot be estimated from the available data
Very common: (occurring in more than 1 in 10 people):
increased intraocular pressure, after 2 weeks of treatment
Common: (occurring in 1 to 10 people in 100):
discomfort, irritation, burning, stinging, itching, and visual disturbances after instillation. These symptoms are usually transient and mild.
Uncommon: (occurring in 1 to 10 people in 1,000):
allergic reactions or hypersensitivity to one of the ingredients of the eye drops, delayed healing, cataract (clouding of the lens), inflammation, glaucoma.
Rare: (occurring in less than 1 in 10,000 people):
conjunctivitis, mydriasis (pupil dilation), facial edema, ptosis (drooping eyelid), uveitis (inflammation of the uvea), corneal calcification, keratopathy (corneal disease), changes in corneal thickness, corneal edema, corneal ulceration, corneal perforation.
In patients with severe damage to the transparent, anterior part of the eye (cornea), phosphates may, in very rare cases, cause corneal clouding due to calcium deposition during treatment.
If the patient experiences any side effects, including any side effects not listed in the leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Post-Marketing Surveillance of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, e-mail: ndl@urpl.gov.pl
Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. Do not use Dexafree after the expiry date stated on the single-dose container after EXP. The expiry date refers to the last day of the month. After opening the sachet: use the contents of the single-dose containers within 15 days. After opening the single-dose container: use immediately and discard the single-dose container after use. Store the single-dose containers in the sachet to protect them from light. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Dexafree is a clear, colorless to light brown solution for eye drops, available in single-dose containers. Each single-dose container contains 0.4 ml of solution. The box contains 20, 30, 50, or 100 single-dose containers packed in sachets.
LABORATOIRES THEA
12, rue Louis Blériot
63017 CLERMONT-FERRAND Cedex 2
FRANCE
EXCELVISION
27, rue de la Lombardière
ZI la Lombardière
07100 ANNONAY
FRANCE
Laboratoire UNITHER
1 rue de l’Arquerie
50200 COUTANCES
FRANCE
THEA POLSKA Sp. z o.o.
ul. Cicha 7
00-353 Warsaw
Phone: +48 22 642 87 77
Bulgaria, Cyprus, France, Greece, Ireland, Poland, Portugal, Spain, and the United Kingdom .......................
......................................................................................................................................... DEXAFREE
Belgium, Luxembourg, and the Netherlands .................................................... MONOFREE DEXAMETHASON
Austria and Germany ............................................................................................... MONODEX
Italy and Slovenia ............................................................................................... DEXAMONO
Denmark, Finland, and Norway ............................................................................ MONOPEX
Date of last revision of the leaflet 11/2021
Detailed information on this medicine is available on the website of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products: www.urpl.gov.pl
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.